high mobility group nucleosomal binding domain 2 pseudogene 24Genealiases: []
Q-omics provides the consensus-scored HMGN2P24 profile across patient tissues and cancer cell-line models. HMGN2P24 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGN2P24 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, HMGN2P24 RNA expression shows 5,848 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, COAD, and STAD as cancer lineages where HMGN2P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P24 survival associations across molecular data types. HMGN2P24 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P24 RNA expression–survival associations across cancer types. High HMGN2P24 expression shows unfavorable associations in ACC, MESO, LUSC and TGCT, but favorable associations in THCA and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGN2P24 RNA expression.
This table summarizes HMGN2P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P24 shows lower tumor expression in KIRP and higher tumor expression in COAD and LUSC. The COAD box plot shows higher HMGN2P24 RNA expression in tumor versus normal tissue (log2 FC = +0.212, t-test p = .015).
This table shows molecular features associated with HMGN2P24 in patient tissues and cancer cell lines. In patient samples, HMGN2P24 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
